Claudia Zylberberg

BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013.

Akron Biotechnology LLC develops and manufactures biotechnology products and services. The firm offers cGMP products, growth factors and cytokines, proteins and supplements, three-dimensional (3D) scaffolds, protein development, media development, and bioscaffold engineering. The company was founded by Claudia Zylberberg in 2006 and is headquartered in Boca Raton, FL.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

AssureImmune LLC provides stem cell banking and storage services. The firm is a science-based cell preservation industry specializes in the collection, testing and banking of cord blood and adult stem cells. It also specializes in immunology, cellular transplantation. The company was founded by Claudia Zylberberg and Javier Zylberberg and is headquartered in Miami, FL.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.